9425 Administration of 24-hour intravenous infusions of trabectedin (Yondelis®) every 3 weeks in ambulatory patients with mesenchymal tumors via the disposable elastomeric pump Baxter LV10: a feasible, convenient, effective and patient-friendly palliative treatment option

Patrick Schöffski(KU Leuven), A.T. van Oosterom(Fondazione Vincenzo Pansadoro), Linda Cerbone(Carlo Forlanini Hospital), Pascal Wolter(KU Leuven), Robert Paridaens(Cornell University), Herlinde Dumez, M. Stas(KU Leuven), Hans Wildiers(KU Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven)
European Journal of Cancer Supplements
September 1, 2009
10.1016/s1359-6349(09)72013-0
Cited by 1

Related Papers

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k